Back to Results

An Open-Label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNy) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Study category: Heart and Blood Conditions

Is this Study for You?

Let's Get Started!

Details
Age

Child

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Tim Garrington,  MD

Tim Garrington, MD

Study ID

Protocol Number: 19-0105

ClinicalTrials.gov: NCT03312751

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers